The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances …
WEBMay 15, 2011 · Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
The dual EGFR/HER2 inhibitor lapatinib synergistically ... - PubMed
WEBMay 15, 2011 · Panobinostat treatment induced downregulation of EGFR, HER2, and HER3 mRNA and protein through transcriptional and posttranslational mechanisms. In the LoVo KRAS mutant CRC xenograft model, the combination showed greater antitumor activity than either agent alone, with no apparent increase in toxicity.
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances …
WEBMay 5, 2011 · Panobinostat treatment induced downregulation of EGFR, HER2 and HER3 mRNA and protein through transcriptional and post-translational mechanisms. In the LoVo KRAS mutant CRC xenograft model, the combination demonstrated greater antitumor activity than either agent alone, with no apparent increase in toxicity.
HER2 - Wikipedia
WEBHER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8]
The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes ...
WEBJun 17, 2009 · Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2. This study evaluated the therapeutic potential of lapatinib, alone and in combination with SN-38, the active metabolite of irinotecan (CPT-11), in colon and gastric cancer cell lines.
Novel immunotherapeutics against LGR5 to target multiple cancer …
WEBAug 21, 2024 · The co-expressed LGR5 and HER2 in LoVo cells enabled us to directly compare the kinetics of endogenous LGR5 internalisation relative to the HER2 receptor by incubating LoVo cells with Fl-α-LGR5v4 and Fl-α-HER2 over a 180-min time course.
Establishment and characterization of 18 human colorectal
WEBApr 22, 2020 · Several CRC cell lines such as HCT‐116, LoVo, SW‐480, and WiDr have accelerated the CRC research. Nevertheless, those accessible CRC cell lines are somewhat obsolete and possibly acquire ...
Dual anti-HER2/EGFR inhibition synergistically increases ... - Nature
WEBFeb 14, 2024 · These results highlight the potential for combination anti-HER2 and anti-EGFR inhibition in HNSCC and in cancers that overexpress both HER2 and EGFR (i.e. ovarian cancer and trastuzumab...
Multi-omics of 34 colorectal cancer cell lines - a resource for ...
WEBJul 6, 2017 · The use of HER2-inhibitors together with the kinase inhibitor lapatinib was recently described as a treatment option in HER2 amplified, KRAS wild-type metastatic CRC in a phase 2 trial . We also observe that Colo678 have high ADAM10 expression, suggested to be involved in acquired resistance to HER2-inhibition in breast cancer models.
(PDF) The dual EGFR/HER2 tyrosine kinase inhibitor
WEBMembers of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER-2.